All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know AML.

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub

Brought to you by Scientific Education Support

Scientific Education Support

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Kura Oncology, Syndax, Abbvie, Thermo Fisher and Johnson & Johnson. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My AML Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View AML content recommended for you

TCT 2023

Share:

Feb 15, 2023

X post image

28 Mar 2023

📊 At #Tandem23, Sergio Giralt presented data from the SIERRA trial of Iomab-B conditioning prior to HSCT in patients with R/R AML.
See our entire visual abstract here 👉 https://t.co/Ug7cq9CgY9.
#leusm

X post image

15 Mar 2023

We report recent data from two trials of Orca-T for the treatment of patients with hematologic malignancies and both matched and 7/8 mismatched allo-HSCT donors, as presented at #Tandem23.
Read more here 👉 https://t.co/Y1jARo7XFS.
#leusm

X post image

13 Mar 2023

#Tandem23 | We hope you enjoyed following our live updates and congress coverage

In case you missed it, catch up on our key points and insights below:

Click here 👉 https://t.co/ZJJrgD44va

#Tandem23 #AML #AMLsm #leusm

X post image

20 Feb 2023

📢 We hope you enjoyed our live coverage of the 2023 Tandem Meetings in Orlando, Florida, US!

Stay tuned for key points and insights raised during the congress.

#AMLsm #leusm #Tandem23

X post image

18 Feb 2023

CONGRESS #Tandem23 | @GiraltSergio @MSKCancerCenter presents the phase III Sierra trial of iomab-B before allo-HCT vs SOC in older pts with active or R/R AML. In the Iomab-B arm 74.6% achieved CR vs 6.3% in the placebo arm. Median OS doubled with iomab-B arm vs placebo #leusm

X post image

18 Feb 2023

Congress | #Tandem23 Gong He, @UChicagoMed presents a poster on a retrospective analysis of FLT3 inhibitor maintenance after allo-HSCT in pts with FLT3-mutated AML. Pts who received FLT3 inhibitor maintenance had improved adjusted OS when compared with pts who did not. #leusm

X post image

18 Feb 2023

Congress | #Tandem23 @mlblack1_b @cityofhope shares a poster on a retrospective analysis of outcomes in pts with MRD+ AML undergoing allo-HSCT with fludarabine and melphalan based conditioning compared to radiation-based MAC. #leusm #medicalcongress

X post image

17 Feb 2023

Congress | #Tandem23 Rawan Al-Omari @pmcancercentre presents a poster on a retrospective analysis of 455 pts with AML who underwent allo-HSCT. Results suggest that a time period from diagnosis to transplant of <3.5 months had a positive impact on OS, NRM, and GRFS. #leusm #AMLsm

X post image

17 Feb 2023

Congress | #Tandem23 Shannon McCurdy, @PennMedicine discusses Fried’s frailty phenotype (FFP) over time after HSCT for older pts. Most older pts had a decline in their FFP 1 month post HSCT. Being frail at 3 or 6 months post-HSCT was associated with inferior subsequent OS. #leusm

X post image

17 Feb 2023

Congress | #Tandem23 Everett Meyer, @StanfordMed highlights data from a phase Ib and phase II study of Orca-T. After a median follow-up of 1 year, Orca-T demonstrated robust GvL and GvI effects with reduced GvHD and NRM. #leusm #medicalcongress

X post image

17 Feb 2023

Congress | #Tandem23 @NaimaHashiMD @MayoClinic @MayoMN_IMRES present a poster on an analysis of 53 pts who experienced post-transplant relapse and received at least one dose of DLI. Results indicate that DLI treatment is effective for disease control post-allo-HSCT. #leusm #AMLsm

X post image

17 Feb 2023

Congress | #Tandem23 @Dr_LvMeng @pku1898 presents data from a phase II study which showed that “Mega-Dose 400mg/m2” decitabine following allo-HSCT in pts with R/R AML had promising efficacy and safety. #leusm #AMLsm

X post image

17 Feb 2023

Congress | #Tandem23 @LoriMuffly @StanfordMed discusses results from a phase I study which demonstrated that targeting CD117 with briquilimab together with TBI and fludarabine is safe, well-tolerated, and efficacious in older pts undergoing NMA HSCT in CR. #leusm

X post image

17 Feb 2023

Congress | #Tandem23 @elias_shlomo @Hadassah shares a poster on factors that affect outcomes of allo-HSCT in pts with R/R AML. Circulating blasts and elevated ferritin at the time of allo-HSCT were associated with increased NRM and inferior OS. #leusm #AMLsm

X post image

16 Feb 2023

Congress | #Tandem23 Boglarka Gyurkocza, @MSKCancerCenter presents a poster on a prospective analysis of barriers to HSCT. The main barrier was disease control, followed by early death. Donor availability was not a barrier. 66% of recommended pts proceeded to HSCT. #leusm #AMLsm

X post image

16 Feb 2023

Congress | #Tandem23 Richard Schlenk, @DKFZ presents a poster on a post-hoc analysis of the QuANTUM-First trial. In pts who underwent allo-HSCT in CR1, quizartinib improved OS vs placebo. Quizartinib improved OS vs placebo irrespective of allo-HSCT in CR1 or pre-allo-HSCT MRD.

X post image

16 Feb 2023

Congress | #Tandem23 Everett Meyer, @StanfordMed presents data from a phase I/II study of Orca-T with tacrolimus and MMF prophylaxis. Pts with 7/8 HLA mismatched donors receiving MAC followed by Orca-T had similar outcomes to Orca-T in pts with 8/8 matched donors. #leusm

X post image

16 Feb 2023

Congress | #Tandem23 @nagler_EBMT @sheba_medical compares outcomes of haploSCT with PTCy in adult pts with sAML vs de novo AML using the EBMT registry. Outcomes were similar between the two groups suggesting that haploSCT with PTCy may overcome the poor prognosis of sAML. #leusm

X post image

16 Feb 2023

Congress | #Tandem23 @BilalAbidMD @MedicalCollege @CIBMTR presents data from a retrospective analysis of younger MUDs vs older MSDs in older pts with AML. Younger MUDs were associated with relapse reduction and a stronger GVL effect when compared with older MSDs. #leusm #AMLsm

X post image

14 Feb 2023

📢 The @AML_Hub will be virtually covering the 2023 Tandem Meetings on February 15–19 in Orlando, Florida, US.

Watch out for any updates and coverage throughout the days!

#AMLsm #leusm #Tandem23

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

TCT 2023 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.

Clinical trials in AML - match patients with relevant trials

Newsletter

Subscribe to get the best content delivered to your inbox